These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34302920)

  • 1. Natural Killer Cells in Cancer and Cancer Immunotherapy.
    Raskov H; Orhan A; Salanti A; Gaggar S; Gögenur I
    Cancer Lett; 2021 Nov; 520():233-242. PubMed ID: 34302920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
    Zhang J; Zheng H; Diao Y
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
    Obajdin J; Davies DM; Maher J
    Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
    Mantesso S; Geerts D; Spanholtz J; Kučerová L
    Front Immunol; 2020; 11():607131. PubMed ID: 33391277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
    Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
    J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
    Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
    Front Immunol; 2021; 12():732135. PubMed ID: 34925314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
    Moscarelli J; Zahavi D; Maynard R; Weiner LM
    Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
    Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
    Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the NK cell platform for cancer immunotherapy.
    Myers JA; Miller JS
    Nat Rev Clin Oncol; 2021 Feb; 18(2):85-100. PubMed ID: 32934330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-expressing NK cells for cancer therapy: a new hope.
    Xia J; Minamino S; Kuwabara K
    Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.